Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.75 |
| ▸ | L3MBTL3 | Q96JM7 | 5/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.38 |
| ▸ | KHK | P50053 | 4/20 | 0.33 |
| ▸ | MBTD1 | Q05BQ5 | 2/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
| ▸ | ARG1 | P05089 | 1/20 | 0.31 |
| ▸ | ARG2 | P78540 | 1/20 | 0.31 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.31 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1447785 | 1.00 | HTR6 (0.75) | HTR6L3MBTL3L3MBTL1KHKMBTD1 | |
| SCHEMBL238942 | 1.00 | HTR6 (0.75) | HTR6L3MBTL3L3MBTL1KHKMBTD1 | |
| Hydrochloric Acid SCHEMBL3335525 | 0.98 | HTR6 (0.72) | HTR6L3MBTL3L3MBTL1KHKMBTD1 | |
| SCHEMBL714244 | 0.98 | HTR6 (0.72) | HTR6L3MBTL3L3MBTL1KHKMBTD1 | |
| Hydrochloric Acid SCHEMBL1736189 | 0.98 | HTR6 (0.72) | HTR6L3MBTL3L3MBTL1KHKMBTD1 | |
| Hydrochloric Acid SCHEMBL1809050 | 0.98 | HTR6 (0.72) | HTR6L3MBTL3L3MBTL1KHKMBTD1 | |
| SCHEMBL1094767 | 0.98 | HTR6 (0.72) | HTR6L3MBTL3L3MBTL1KHKMBTD1 | |
| Hydrochloric Acid SCHEMBL17311103 | 0.98 | HTR6 (0.72) | HTR6L3MBTL3L3MBTL1KHKMBTD1 | |
| SCHEMBL10265670 | 0.98 | HTR6 (0.72) | HTR6L3MBTL3L3MBTL1KHKMBTD1 | |
| Hydrochloric Acid SCHEMBL1814485 | 0.98 | HTR6 (0.72) | HTR6L3MBTL3L3MBTL1KHKMBTD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 340 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1213684-A | Chemical Mechanical Polishing Composition | CHANGXING CHEMICAL IND CO LTD (CN) | 1999-04-14 | — | — | CN | claimed |
| EP-4027995-B1 | HPK1 ANTAGONISTS AND USES THEREOF | NIMBUS SATURN INC (US) | 2026-05-27 | — | — | EP | disclosed |
| US-20260109686-A1 | PYRIDAZIN-3(2H)-ONE AND PYRIDIN-2(1H)-ONE PARP INHIBITOR COMPOUNDS | AZKARRA THERAPEUTICS, INC. (US) | 2026-04-23 | — | — | US | disclosed |
| US-20250353841-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | HUFF SARAH ELIZABETH (US) | 2025-11-20 | — | — | US | disclosed |
| US-20250304577-A1 | TYK2 INHIBITORS | BIOGEN MA INC. | 2025-10-02 | — | — | US | disclosed |
| EP-4618755-A1 | INHIBITORS AND DEGRADERS OF PIP4K PROTEIN | Larkspur Biosciences, Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| EP-4594314-A1 | PYRIDAZIN-3(2H)-ONE AND PYRIDIN-2(1H)-ONE PARP INHIBITOR COMPOUNDS | Azkarra Therapeutics, Inc. (US) | 2025-08-06 | — | — | EP | disclosed |
| US-20250154169-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. | 2025-05-15 | — | — | US | disclosed |
| CN-119968364-A | Pyridazin-3 (2H) -one and pyridin-2 (1H) -one PARP inhibitor compounds | 阿兹卡拉疗法公司 | 2025-05-09 | — | — | CN | disclosed |
| CN-119874700-A | HPK1 antagonists and uses thereof | 林伯士萨顿公司 | 2025-04-25 | — | — | CN | disclosed |
| US-20040209865-A1 | Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-10-21 | — | — | US | disclosed |
| US-20040186160-A1 | Hexahydro-cyclohepta-pyrrole oxindole as potent kinase inhibitors | SUGEN, INC. | 2004-09-23 | — | — | US | disclosed |
| WO-2004039780-A1 | NOVEL ALKYNE COMPOUNDS HAVING AN MCH ANTAGONISTIC EFFECT AND MEDICAMENTS CONTAINING THESE COMPOUNDS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-05-13 | — | — | WO | disclosed |
| US-20040044031-A1 | N-acyltetrahydroisoquinoline derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-03-04 | — | — | US | disclosed |
| EP-1288202-A1 | N-ACYLTETRAHYDROISOQUINOLINE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2003-03-05 | — | — | EP | disclosed |
| CN-1213684-A | Chemical Mechanical Polishing Composition | CHANGXING CHEMICAL IND CO LTD (CN) | 1999-04-14 | — | — | CN | disclosed |
| US-5476950-A | Aminopyrrolidine compound | DAIICHI SEIYAKU CO., LTD. (JP) | 1995-12-19 | — | — | US | disclosed |
| US-5416222-A | Chemical intermediates to prepare pyridinocarboxylic acid derivatives with high antimicrobial activity and excellent pharmacokinetics | DAIICHI SEIYAKU CO., LTD. (JP) | 1995-05-16 | — | — | US | disclosed |
| US-5380874-A | Pyrrolidine carbamates | DAIICHI SEIYAKU CO., LTD. (JP) | 1995-01-10 | — | — | US | disclosed |
| US-5098912-A | Bactericides for grampositive bacteria | DAIICHI SEIYAKU CO., LTD. (JP) | 1992-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044031-A1 | N-acyltetrahydroisoquinoline derivatives | HCRTR2, HCRTR1, OPRL1 | HTR6 173/4885L3MBTL3 2215/4885L3MBTL1 1985/4885 |
| US-20250353841-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | HTT, HYPK, ATXN2 | HTR6 169/4885L3MBTL3 3700/4885L3MBTL1 2595/4885 |
| US-20250304577-A1 | TYK2 INHIBITORS | TYK2, JAK2, JAK1 | HTR6 2272/4885L3MBTL3 3014/4885L3MBTL1 2886/4885 |
| US-20260109686-A1 | PYRIDAZIN-3(2H)-ONE AND PYRIDIN-2(1H)-ONE PARP INHIBITOR COMPOUNDS | PARP2, PARP1, PARP11 | HTR6 122/4885L3MBTL3 909/4885L3MBTL1 523/4885 |
| US-20040209865-A1 | Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds | MCHR1, MCHR2, NPY1R | HTR6 172/4885L3MBTL3 1187/4885L3MBTL1 984/4885 |
| US-20250154169-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | RBM17, SNRPA, SNRPA1 | HTR6 2732/4885L3MBTL3 163/4885L3MBTL1 245/4885 |
| US-20040186160-A1 | Hexahydro-cyclohepta-pyrrole oxindole as potent kinase inhibitors | MAP3K15, MAP3K20, MAP3K19 | HTR6 1239/4885L3MBTL3 3096/4885L3MBTL1 3649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.